Eszopiclone

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of eszopiclone
General
Non-proprietary name Eszopiclone
other names
  • ( S ) -6- (5-chloro-2-pyridyl) -6,7-dihydro-7-oxo-5 H -pyrrolo [3,4- b ] pyrazin-5-yl-4-methyl-1-piperazinecarboxylate
  • Eszopiclonum ( Latin )
Molecular formula C 17 H 17 ClN 6 O 3
External identifiers / databases
CAS number 138729-47-2
EC number 620-471-1
ECHA InfoCard 100.149.304
PubChem 969472
DrugBank DB00402
Wikidata Q413184
Drug information
ATC code

N05 CF04

Drug class

Hypnotic sedative

properties
Molar mass 388.81 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
08 - Dangerous to health 07 - Warning

Caution

H and P phrases H: 302 + 312 + 332-315-319-335-361
P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Eszopiclone is a drug from the group of sleeping pills and its effects are related to the benzodiazepines .

Chemically, the substance belongs to the cyclopyrrolone class . Of the two enantiomers [( R ) - and ( S ) - zopiclone ], only the ( S ) -enantiomer eszopiclone has a sleep-inducing effect. By using eszopiclone, the dose can be reduced significantly compared to the use of the racemic mixture . Eszopiclone has been approved as a sleeping aid in the USA since 2005 and is available there under the brand name Lunesta . The manufacturer withdrew an application for approval in the EU after the Committee for Medicinal Products for Human Use of the European Medicines Agency wanted to approve the drug, but refused the status of a “new active ingredient” for the eszopiclone it contained. As a result, the manufacturer, Sepracor Pharmaceuticals , would not have been able to benefit from the ten-year market exclusivity granted to drugs with new drugs.

Individual evidence

  1. Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . What is shown is a label for 1-Piperazinecarboxylic acid, 4-methyl-, 6- (5-chloro-2-pyridinyl) -6,7-dihydro-7-oxo-5H-pyrrolo [3,4 -b] pyrazin-5-yl ester, (S) - in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on February 7, 2020.
  2. FDA approved labeling text for LUNESTA ® (eszopiclone) 2009 .
  3. Sepracor Pharmaceuticals Ltd withdraws its marketing authorization application for Lunivia (eszopiclone) , May 15, 2009 (PDF, English).
  4. Questions and answers on withdrawing the application for approval for Lunivia (PDF; 43 kB), May 29, 2009.